article thumbnail

Process improvements and in-person monitoring help U.S. pharmaceutical company achieve on time for Phase III clinical trials

Syner-G

pharmaceutical company to oversee a 6 month, DS manufacturing as Person-In- Plant (PIP) and assist with preparation of associated submission documents related to Phase III clinical trial batches. Download The Case Study The post Process improvements and in-person monitoring help U.S.

article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Balancing cost and value with TCO

Express Pharma

This involves identifying critical quality attributes and process parameters and implementing strong controls for consistent product quality. Supply chain management: Pharmaceutical companies should focus on building resilient and flexible supply chains capable of adapting to market fluctuations and disruptions.

article thumbnail

Developing a first-in-class small molecule drug for inflammatory disease

European Pharmaceutical Review

To ensure an efficient process, MyMD works closely with the contract manufacturing organisation (CMO) focusing on automation and process improvement. All pharmaceutical companies want to save on the cost of production, but not at the expense of quality. This allows us to stay on top of quality control.

article thumbnail

Patient Centricity for Pharma Marketing – Quiz

PharmaState Academy

a) Maximizing Profits through maximum patient's care b) Putting Patients First c) Regulatory Compliance and patient outcome d) Internal Processes improvement to improve patient's health outcomes 5 / 20 How can patient-centric marketing contribute to better healthcare outcomes?

Dosage 59
article thumbnail

Considerations for a successful tech transfer of a biologics upstream process

European Pharmaceutical Review

The emergence of huge pharmaceutical companies with discrete centres of excellence in geographically dispersed locations has upended the classic model of one-stop shopping for all development functions. An example of the structured and modular tech transfer approach is shown in Figure 2.

article thumbnail

The next frontier: Global leadership in biopharma

Express Pharma

Biswas outlines, “Adopting advanced manufacturing technologies, including continuous processing, digitally programmed manufacturing systems (MES) and deep learning based continuous process improvements are factors that hold immense promise for transforming biopharma production.